HEXA-BETALIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HEXA-BETALIN (HEXA-BETALIN).
Hexa-Betalin is a combination of six B vitamins (B1, B2, B3, B5, B6, B12) that act as cofactors in various enzymatic reactions involved in energy metabolism, neurotransmitter synthesis, and nerve function.
| Metabolism | Each vitamin is metabolized separately; B1 is phosphorylated, B2 is converted to FMN/FAD, B3 to NAD/NADP, B5 to coenzyme A, B6 to pyridoxal phosphate, B12 binds to haptocorrin and intrinsic factor. |
| Excretion | Renal excretion of unchanged drug accounts for 75-85% of the administered dose. Biliary/fecal elimination is minimal, less than 5%. |
| Half-life | Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function. This short half-life necessitates frequent dosing for sustained therapeutic effect. Half-life is prolonged in renal impairment. |
| Protein binding | Approximately 20-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5-1.0 L/kg, indicating distribution into total body water and moderate tissue binding. |
| Bioavailability | Oral bioavailability is 30-50% due to extensive first-pass metabolism. Intravenous administration yields 100% bioavailability. |
| Onset of Action | Oral administration: Onset of action occurs within 1-2 hours. Intravenous administration: Onset is rapid, within 5-15 minutes. |
| Duration of Action | Duration of action is 6-8 hours following oral administration and 4-6 hours following intravenous administration, correlating with its half-life. Clinical effects diminish as plasma concentrations fall below therapeutic threshold. |
Dosage forms: Tablet 10mg, 50mg, 100mg, 250mg; Injection 50mg/mL. Usual adult dose: 100–250mg orally 1–3 times daily. Maximum 1000mg/day. IV/IM: 50–250mg every 6–8 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended. Use caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation of pyridoxine metabolites; monitor for neuropathy. |
| Liver impairment | No specific dose adjustment recommended. Use caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Oral: 10–50mg once daily (weight-based: 0.5–2 mg/kg/day). IV/IM: 10–25mg once daily; maximum 50mg/day. In pyridoxine-dependent seizures: 30–100 mg/kg IV initially, then 10–30 mg/kg/day divided q4–6h. |
| Geriatric use | Start at low end of dosing range (10–50mg/day) due to age-related decline in renal function and increased risk of adverse effects (e.g., sensory neuropathy). Monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HEXA-BETALIN (HEXA-BETALIN).
| Breastfeeding | Pyridoxine is excreted into breast milk in concentrations that parallel maternal plasma levels. M/P ratio approximately 1.0. Recommended doses (≤25 mg/day) are safe. High maternal doses may suppress lactation due to prolactin inhibition. |
| Teratogenic Risk | Hexa-Betalin (pyridoxine) is generally considered low risk. No evidence of human teratogenicity at recommended doses. First trimester: No increased risk of major malformations. Second/Third trimester: Use for nausea/vomiting is safe. High doses (>100 mg/day) may cause neonatal seizures with pyridoxine dependency. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component
| Precautions | Use with caution in patients with malabsorption syndromes; monitor for allergic reactions; avoid excessive doses of B6 to prevent neuropathy. |
Loading safety data…
| Fetal Monitoring |
| No specific fetal monitoring required at standard doses. For high-dose therapy (>100 mg/day), monitor maternal sensory neuropathy. No routine monitoring during pregnancy. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Excessive pyridoxine may cause reversible anovulation or menstrual irregularities at very high doses (>200 mg/day). |